Six dementia patients received a controversial gene therapy injection in Mexico City, according to a biotech CEO. (STAT)
Alzheimer’s anti-amyloid treatment appeared to benefit from enhanced lymphatic vessels, a mouse study suggested. (Nature)
Cladribine (Mavenclad) did not impair humoral response to COVID-19 vaccination in patients with multiple sclerosis (MS), but ocrelizumab (Ocrevus) and fingolimod (Gilenya) did, a small study in Israel showed. (Therapeutic Advances in Neurological Disorders)
Median SARS-CoV-2 antibody response was lower for MS patients on ocrelizumab than it was for other MS patients with COVID-19. (JAMA Neurology)
An investigational Alzheimer’s treatment known as BPN14770, a phosphodiesterase-4D inhibitor, boosted cognition in a phase II trial of people with fragile X syndrome. (Nature Medicine)
A mobile device app detected distinctive eye-gaze patterns in toddlers with autism spectrum disorder. (JAMA Pediatrics)
Variation in tau pathology was common, systematic, and fell into four distinct patterns in Alzheimer’s disease, a review of more than 1,600 tau PET scans showed. (Nature Medicine)
How to recruit people who don’t know they qualify for a study? Researchers talk about finding the right participants for early Alzheimer’s trials. (New York Times)
“Ghosts” or presence hallucinations stemmed from altered frontotemporal connectivity in people with Parkinson’s disease. (Science Translational Medicine)
The FDA did not approve subcutaneous administration of the MS drug natalizumab (Tysabri), Biogen said.
A federal appeals court ruled that the Environmental Protection Agency must ban chlorpyrifos from food crops unless the agency can demonstrate safety. The pesticide has been linked to neurological damage in children. (Washington Post)
The Art of the Brain virtual exhibition, a collection of photographs, paintings, and illustrations about the brain from the Icahn School of Medicine at Mount Sinai in New York City, continues until May 28.
Source: MedicalNewsToday.com
